Simufilam
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Simufilam
- Molecular weight
- 259.35
- Structure (SMILES)
- CN1CCC2(CC1)NCC(=O)N2Cc1ccccc1
- filora
- Filora
- c 0105
- C-0105
- c0105
- C0105
- c0105m
- C0105M
- pti 125
- pti 910
- PTI-125
- PTI-910
- simufilam
- Simufilam
- simufilam [INN]
- SIMUFILAM [USAN]
- Simufilam [WHO-DD]
- simufilam inn
- simufilam usan
- simufilam who dd
- CAS registry numbers
- 1224591-33-6
- ChEMBL ID
- CHEMBL4650230
- InChIKey
- BSQPTZYKCAULBH-UHFFFAOYSA-N
- PubChem compound IDs
- 46195331
- FDA ingredient codes (UNII)
- 6NV440YIO0
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -filam
Mechanisms of action
- Mechanism
- Filamin-A positive modulator
- Action type
- POSITIVE_MODULATOR
- Target
- Filamin-A
- Protein identifier
- P21333
Open Targets mechanisms
- Mechanism
- Filamin-A positive modulator
- Action type
- POSITIVE MODULATOR
- Target
- Filamin-A
- Condition
- Neurogenic Inflammation
- Highest recorded phase
- 1
- Subject identifier
- D020078
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Alzheimer Disease
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition identifier
- EFO_0000616
- Condition identifier
- HP_0001399
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005070
- NCT03748706
- NCT03784300
- NCT04079803
- NCT04388254
- NCT04994483
- NCT05026177
- NCT05352763
- NCT05575076
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 35.58
- Calculated partition coefficient (ALogP)
- 1.04
- Calculated partition coefficient (XLogP)
- 1.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 19
- Molecular formula
- C15H21N3O
- Monoisotopic mass
- 259.168462302
- Natural product
- No
Related records
Trials (11)
- A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
- A Safety Study of PTI-125 in Healthy Volunteers
- Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers
- Open-label Extension for Phase 3 Clinical Trials of Simufilam
- Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
- Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
- PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
- PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
- Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
- Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
- Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
In development for (2)
- Alzheimer disease Phase 3
- Neoplasm Phase 1
Targets (1)
- FLNA Filamin-A positive modulator